Last reviewed · How we verify
Adjuvants, Anesthesia
Adjuvants, Anesthesia is a Anesthetic adjuvant (class includes multiple drug types: opioids, benzodiazepines, neuromuscular blockers, alpha-2 agonists) Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Adjunctive use in general anesthesia to enhance anesthetic efficacy and reduce primary anesthetic requirements, Perioperative analgesia and anxiolysis.
Adjuvants in anesthesia enhance or modify the effects of primary anesthetic agents to improve anesthetic depth, reduce required doses, and provide additional therapeutic benefits such as analgesia or muscle relaxation.
Adjuvants in anesthesia enhance or modify the effects of primary anesthetic agents to improve anesthetic depth, reduce required doses, and provide additional therapeutic benefits such as analgesia or muscle relaxation. Used for Adjunctive use in general anesthesia to enhance anesthetic efficacy and reduce primary anesthetic requirements, Perioperative analgesia and anxiolysis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Adjuvants, Anesthesia |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Anesthetic adjuvant (class includes multiple drug types: opioids, benzodiazepines, neuromuscular blockers, alpha-2 agonists) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Anesthetic adjuvants are drugs administered alongside primary anesthetics to potentiate anesthetic effects, reduce side effects, or provide complementary actions. Common adjuvants include opioids for analgesia, benzodiazepines for anxiolysis and sedation, and neuromuscular blocking agents for muscle relaxation. By combining agents with different mechanisms, adjuvants allow lower doses of each drug, thereby reducing toxicity and adverse effects while achieving optimal anesthetic conditions.
Approved indications
- Adjunctive use in general anesthesia to enhance anesthetic efficacy and reduce primary anesthetic requirements
- Perioperative analgesia and anxiolysis
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Nausea and vomiting
- Delayed recovery
Key clinical trials
- Comparison of Intrathecal Nalbuphine Versus Intrathecal Tramadol as Adjuvants in Subarachnoid Block for Lower Limb Orthopaedic Surgeries (NA)
- The Impact of Saline Temperature and Local Anesthetic Adjuvants on Postoperative Shoulder Pain and Inflammatory Marker Levels Following Laparoscopic Cholecystectomy (NA)
- Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients (PHASE4)
- Sublingual Atropine Bioequivalence by Route of Administration (SABER) (PHASE1)
- Comparison Between Intrathecal Magnesium Sulphate & Dexmedetomidine in DHS (PHASE3)
- Intrathecal Dexmedetomidine vs Epinephrine (PHASE4)
- Prilocaine for Sphenopalatine Ganglion Block in Endoscopic Hypophysectomy (NA)
- D-FAB-POUR Trial: Dexmedetomidine vs Fentanyl as Adjuvants to Bupivacaine on Postoperative Urinary Retention (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvants, Anesthesia CI brief — competitive landscape report
- Adjuvants, Anesthesia updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Adjuvants, Anesthesia
What is Adjuvants, Anesthesia?
How does Adjuvants, Anesthesia work?
What is Adjuvants, Anesthesia used for?
Who makes Adjuvants, Anesthesia?
What drug class is Adjuvants, Anesthesia in?
What development phase is Adjuvants, Anesthesia in?
What are the side effects of Adjuvants, Anesthesia?
Related
- Drug class: All Anesthetic adjuvant (class includes multiple drug types: opioids, benzodiazepines, neuromuscular blockers, alpha-2 agonists) drugs
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Anesthesiology
- Indication: Drugs for Adjunctive use in general anesthesia to enhance anesthetic efficacy and reduce primary anesthetic requirements
- Indication: Drugs for Perioperative analgesia and anxiolysis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing